TrialJNCI cancer spectrum2024

Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers.

Anant Ramaswamy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.